| Discontinuing donepezil or starting memantine for Alzheimer's disease. | |
| | |
MedLine Citation:
|
PMID: 22670912 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
To the Editor: In the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO) study, Howard and coauthors (March 8 issue)(1) found that the magnitude of benefit, as assessed with the Standardized Mini-Mental State Examination (SMMSE) and the Bristol Activities of Daily Living Scale (BADLS), was more favorable in patients who continued donepezil as compared with those who were assigned to memantine. However, only patients who had already received donepezil for more than 3 months were recruited, which plausibly suggests that those in whom donepezil had an unfavorable side-effect profile, and possibly those who did not show any indication . . . |
| | |
Authors:
|
Mariel M Finucane; Thomas E Finucane |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The New England journal of medicine Volume: 366 ISSN: 1533-4406 ISO Abbreviation: N. Engl. J. Med. Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-06-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 2227-8 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Discontinuing donepezil or starting memantine for Alzheimer's disease.
Next Document: Prostate-Cancer Mortality after PSA Screening.